Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Vectibix (panitumumab) Market Growth Potential: How Will Market Size Change Through 2030?
The market for Vectibix, known generically as panitumumab, has experienced notable expansion over recent years. By 2025, its market value stood at $1.37 million, and this figure is projected to climb to $1.48 million by 2026, representing a compound annual growth rate (CAGR) of 8.0%. Several key factors fueled growth during the historic period, including its approval for treating metastatic colorectal cancer, demonstrated effectiveness in inhibiting EGFR, strong uptake among oncology specialists, a growing prevalence of colorectal cancer cases, and continued progress in the development of targeted cancer therapies.
The market for vectibix (panitumumab) is projected to experience robust expansion over the coming years, reaching $2 million by 2030 with a compound annual growth rate (CAGR) of 7.7%. This forecasted growth is driven by several factors, including higher rates of precision medicine adoption, advancements in cancer diagnostics, inclusion in new cancer treatment areas, increasing expenditures on oncology healthcare, and better patient stratification methods. Key trends anticipated in this period involve a growing reliance on targeted EGFR therapies, broadening access to precision oncology treatments, increased biomarker-guided patient selection, wider use of monoclonal antibodies within hospital settings, and the integration of combination therapies in cancer care protocols.
Download A Free Sample Report For Comprehensive Market Insights:
Vectibix (panitumumab) Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated growth of the vectibix (panitumumab) market is being driven by the rising occurrence of colorectal cancer. This disease begins in the colon or rectum, frequently originating from precancerous polyps, and its increasing frequency is linked to unhealthy lifestyle choices such as poor nutrition, physical inactivity, and obesity, all of which contribute to a higher likelihood of polyp formation and cancer progression. Panitumumab, also known as vectibix, is a monoclonal antibody designed to target and block the epidermal growth factor receptor (EGFR), thereby decelerating tumor growth and disease advancement in individuals with wild-type KRAS tumors, offering a viable treatment alternative for those who fail to respond to standard chemotherapy. Data from the American Cancer Society, a nonprofit organization based in the United States, revealed in February 2025 that the projected number of new colorectal cancer cases stood at 154,270, up from 152,810 in 2024, highlighting this upward trend. Consequently, the escalating prevalence of colorectal cancer is set to fuel expansion in the vectibix (panitumumab) market.
The vectibix (panitumumab) market is experiencing growth fueled by the increasing appetite for personalized medicine. This healthcare approach tailors treatments and strategies to align with each patient’s distinct traits, needs, and preferences, and its rising adoption stems from progress in genomic technologies that allow for accurate identification of genetic differences and customized therapeutic interventions. Panitumumab is employed in personalized medicine by specifically binding to the epidermal growth factor receptor (EGFR) on cancer cells, facilitating targeted care for metastatic colorectal cancer patients whose tumors exhibit wild-type EGFR, thus enhancing treatment effectiveness while reducing unnecessary adverse effects based on individual genetic profiles. As reported in February 2024 by the Personalized Medicine Coalition (PMC), a US-based nonprofit, the FDA authorized 26 novel personalized medicines in 2023, a notable jump from the 12 approvals in 2022. Therefore, the growing demand for personalized medicine is advancing the vectibix (panitumumab) market.
Vectibix (panitumumab) Market Segment Analysis Highlighting Growth Areas
The vectibix (panitumumab) market covered in this report is segmented –
1) By Distribution Channel: Hospital Pharmacies, Online Pharmacies
2) By Application: Colorectal Cancer Treatment, Other Cancer Treatments
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Vectibix (panitumumab) Market Trends: What Is Shaping Future Industry Growth?
Leading firms in the vectibix (panitumumab) market are prioritizing the creation of advanced companion diagnostics to facilitate targeted therapies, boost treatment effectiveness, and safeguard patient well-being. These companion diagnostics are tests that deliver crucial data for the safe and effective application of a corresponding therapeutic product. For example, in October 2023, EntroGen Inc., a biotechnology company based in the US, secured approval from the U.S. Food and Drug Administration (FDA) for the CRCdx RAS Mutation Detection Kit as a companion diagnostic tailored for Vectibix (panitumumab). The CRCdx RAS mutation detection kit serves as a distinctive molecular diagnostic tool, marking a major stride in precision medicine for individuals with colorectal cancer (CRC). It stands as the first real-time PCR-based test in the U.S. to achieve premarket approval (PMA) and completely satisfy the biomarker identification criteria for Vectibix. This innovative kit is engineered to precisely detect mutations in KRAS and NRAS exons 2, 3, and 4, delivering high levels of sensitivity and specificity. It empowers clinicians to effectively pinpoint patients who are most likely to gain from vectibix therapy, thereby reducing unnecessary side effects and treatment expenses.
Vectibix (panitumumab) Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the vectibix (panitumumab) market are Amgen Inc.
Access The Complete Vectibix (panitumumab) Market Report:
Vectibix (panitumumab) Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the vectibix (panitumumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model